Loading
Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial.
Developed by Shanghai Allist Pharmaceuticals; approved by the NMPA in March 2021 for EGFR T790M-positive NSCLC after earlier EGFR inhibitors and in June 2022 for first-line EGFR-mutant NSCLC on FURLONG (358 patients: median progression-free survival 20.8 versus 11.1 months with gefitinib, hazard ratio 0.44). A higher dose is being developed for EGFR exon 20 insertions, where ArriVent BioPharma holds ex-China rights and is running the global FURVENT phase 3 trial. Adjuvant and central nervous system studies continue.
Irreversible third-generation EGFR inhibitor active against sensitising mutations and T790M with a trifluoroethoxy pyridine that improves brain penetration; its main metabolite is also active. Connects to EGFR.
1.Furmonertinib slips into a pocket on EGFR.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2021 | EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy |
| China | 2022 | First-line EGFR exon 19 deletion or L858R NSCLC (FURLONG) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Furmonertinib" OR ABSTRACT:"Furmonertinib" OR TITLE:"Ivesa" OR ABSTRACT:"Ivesa" OR TITLE:"AST2818" OR ABSTRACT:"AST2818" OR TITLE:"alflutinib" OR ABSTRACT:"alflutinib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Furmonertinib, not a curated reading list.
Shares FURLONG, EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M), RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), EGFR-mutated non-small-cell lung cancer, EGFR, Small-molecule kinase inhibitors and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.